Figure 6 | Blood Cancer Journal

Figure 6

From: The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

Figure 6

Pracinostat and pacritinib have synergistic effects on AML-induced plasma cytokines/growth factors/chemokines. Plasma levels of a panel of 32 cytokines/growth factors/chemokines were analyzed using the MAP Mouse Cytokine/Chemokine panel from Millipore. Plasma was collected from SCID-beige mice bearing s.c. SET-2 tumors on d18, 3 h post-dose, after chronic dosing with pacritinib and pracinostat from the mice used in the efficacy study described in Figure 4.

Back to article page